Nuwellis (NASDAQ:NUWE – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Nuwellis in a report on Monday, September 21st. One research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock currently has an average rating of “Sell”.
Get Our Latest Stock Report on Nuwellis
Nuwellis Price Performance
NASDAQ:NUWE opened at $4.90 on Friday. Nuwellis has a 12 month low of $2.52 and a 12 month high of $1,556.07. The firm has a market capitalization of $2.65 million, a PE ratio of -0.00 and a beta of 0.03. The business’s fifty day moving average price is $6.03 and its 200 day moving average price is $206.53.
Nuwellis (NASDAQ:NUWE – Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($5.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($122.85) by $117.04. Nuwellis had a negative return on equity of 1,259.16% and a negative net margin of 150.50%. The business had revenue of $2.21 million during the quarter, compared to analysts’ expectations of $2.50 million.
Nuwellis Company Profile
Nuwellis, Inc. is a medical device company focused on fluid management therapies for patients with fluid overload. The company develops and commercializes ultrafiltration technologies designed to remove excess salt and fluid from the blood when conventional diuretic therapy may be inadequate or poorly tolerated. Nuwellis’ principal product is the Aquadex system, including the Aquadex FlexFlow system, a compact ultrafiltration platform used in hospital settings. The system is intended for temporary extracorporeal fluid removal in patients with conditions such as fluid overload associated with heart failure, renal dysfunction, and other critical-care needs.
See Also
- Five stocks we like better than Nuwellis
- Nu Holdings Earnings Show a Compounder Priced Like a Brazil Bet
- Game On: The Hidden Value in Take-Two’s Stock
- LightPath Technologies’ Record Backlog Highlights a Bigger Defense Opportunity
- A 10-Stock Strategy That Balances AI Growth With Cash Flow
Receive News & Ratings for Nuwellis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuwellis and related companies with MarketBeat.com's FREE daily email newsletter.
